26 April 2021

This week in PVD

Claritas Gaining Global Rights to R-107, Varied Nitric Oxide PAH Therapy

Claritas Pharmaceuticals has signed a letter of intent with the Salzman Group to acquire exclusive global rights to develop and market R-107 — a liquid form of nitric oxide — to treat, and possibly reverse, pulmonary arterial hypertension (PAH).

The agreement is expected to come into effect by May 15, pending regulatory approval.

Nitric oxide, a gas naturally found in the body, works as an antiviral, fighting off viruses. Claritas — previously known as Kalytera Therapeutics — initially acquired a license to advance R-107 as a potential treatment of  SARS-CoV-2, the virus that causes COVID-19, and other viral infections.

Nitric oxide also works as a vasodilator: it relaxes and widens blood vessels, so that blood flows more easily through them with less pressure. In studies in an established rat model, R-107 showed an ability to treat PAH by dilating blood vessels and restoring blood pressure in the lungs, Claritas reported in a press release, with  benefits persisting after treatment stopped.

Quick Approval for COVID Vaccines a Concern, Rare Disease Patients Say

More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports.

These findings highlight the need for a greater understanding of the U.S. Food and Drug Administration’s (FDA) emergency use authorization (EUA) process, as all current U.S. vaccines against this virus came via this pathway.


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg